Grant for High-Risk, High-Impact Brain Cancer Research Awarded to Ivy Center Investigator
10 nov. 2022 09h00 HE
|
Ivy Brain Tumor Center
Phoenix, AZ, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Dr. An-Chi Tien, Pharmacodynamics Core Leader of the Ivy Brain Tumor Center, is a recipient of the American Brain Tumor Association’s Discovery Grant,...
Jackie Ng shares her 23-year journey with meningioma in ‘Rising’
02 févr. 2021 00h00 HE
|
Partridge Singapore
KUALA LUMPUR, Malaysia, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Life is unpredictable but, with grit and determination, anything is possible. Jackie Ng came to learn this firsthand during her 23-year...
NX Development Corp. (NXDC) Receives FDA Orphan-Drug Designation for Gleolan® (aminolevulinic acid HCl) in Meningioma
12 janv. 2021 10h10 HE
|
NX Development Corp.
Lexington, KY, Jan. 12, 2021 (GLOBE NEWSWIRE) -- NX Development Corp. (NXDC), a life sciences company wholly owned by photonamic GmbH & Co. KG., today announced FDA orphan-drug designation for...
NX Development Corp. (NXDC) Launches Gleolan (aminolevulinic acid HCl) Meningioma Phase III Clinical Trial (NXDC-MEN-301)
17 nov. 2020 14h12 HE
|
NX Development Corp.
Lexington, KY, Nov. 17, 2020 (GLOBE NEWSWIRE) -- NX Development Corp (NXDC), a life sciences company wholly owned by photonamic GmbH & Co. KG., today announced the enrollment of the first...
National Brain Tumor Society and the Brain Science Foundation Partner to Fund Research for Most Common Brain Tumor Type
19 févr. 2019 12h12 HE
|
National Brain Tumor Society
Boston, MA, Feb. 19, 2019 (GLOBE NEWSWIRE) -- National Brain Tumor Society (NBTS), a leading nonprofit dedicated to the brain tumor community in the United States, today announced a new partnership...